
    
      This study is a retrospective analysis of dialysis dependent CKD patients participating in
      AURORA. The retrospective analysis will be performed using the AURORA study database.

      AURORA was a prospective clinical trial in which dialysis patients were randomly assigned to
      rosuvastatin or placebo, sponsored by AstraZeneca. Patients included in the AURORA study who
      had end stage renal disease (ESRD) and had been treated with regular hemodialysis or
      hemofiltration for at least 3 months. Patients were recruited from approximately 300 centers
      in 25 countries.

      The clinical study data is held by AstraZeneca AB, Sweden.

      No formal sample size calculation was performed. The sample size is based on the available
      data from the AURORA study.
    
  